New hope for young lymphoma patients: targeted treatment trial shows promise
NCT ID NCT01516567
Summary
This study tested a chemotherapy regimen called DA-EPOCH combined with the targeted drug rituximab in children and adolescents with a specific type of lymphoma. The main goal was to see how well this treatment prevented the cancer from coming back or getting worse. Researchers enrolled 47 young patients to measure survival rates and monitor side effects during and after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2nd Dept. of Pediatrics Semmelweis Univ.
Budapest, 1094, Hungary
-
Associazione Italiana di Ematologia ed Oncologia Pediatrica
Padova, 35128, Italy
-
Children Oncology Group Operations centres
Monrovia, Canada
-
Emma Children's Hospital
Amsterdam, 1105 AZ, Netherlands
-
Gustave Roussy
Villejuif, 94805, France
-
Rectorat of Medical University
Wroclaw, Poland
-
Sociedad Española de Hematología y Oncología Pediátricas
Valencia, 46010, Spain
-
University Hospitals Leuven
Leuven, 3000, Belgium
-
University of Birmingham
Birmingham, United Kingdom
Conditions
Explore the condition pages connected to this study.